Neuropathology of Drug Addictions and Substance Misuse, Volume 3
General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse, Emerging Addictions and Non-Drug Addictions
Herausgeber: Preedy, Victor R
Neuropathology of Drug Addictions and Substance Misuse, Volume 3
General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse, Emerging Addictions and Non-Drug Addictions
Herausgeber: Preedy, Victor R
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Neuropathology of Drug Addictions and Substance Misuse, Volume 3: General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse, Emerging Addictions and Non-Drug Addictions is the third of three volumes in this informative series and offers a comprehensive examination of the adverse consequences of the most common drugs of abuse. Each volume serves to update the reader's knowledge on the broader field of addiction as well as to deepen understanding of specific addictive substances. Volume 3 addresses prescription medications, caffeine, polydrug misuse, and…mehr
- Medicinal Usage of Cannabis and Cannabinoids265,99 €
- Neurobiology and Physiology of the Endocannabinoid System271,99 €
- Ari Kalechstein (ed.)Neuropsychology and Substance Use202,99 €
- Handbook of Lifespan Cognitive Behavioral Therapy268,99 €
- Handbook of Cognitive Behavioral Therapy by Disorder268,99 €
- Jahangir MoiniEpidemiology of Brain and Spinal Tumors265,99 €
- Patterning and Cell Type Specification in the Developing CNS and Pns265,99 €
-
-
-
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
- Produktdetails
- Verlag: Elsevier Science
- Seitenzahl: 1106
- Erscheinungstermin: 12. Mai 2016
- Englisch
- Abmessung: 282mm x 221mm x 41mm
- Gewicht: 2449g
- ISBN-13: 9780128006344
- ISBN-10: 012800634X
- Artikelnr.: 44660920
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
- Verlag: Elsevier Science
- Seitenzahl: 1106
- Erscheinungstermin: 12. Mai 2016
- Englisch
- Abmessung: 282mm x 221mm x 41mm
- Gewicht: 2449g
- ISBN-13: 9780128006344
- ISBN-10: 012800634X
- Artikelnr.: 44660920
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
Mechanisms
Section A. General Aspects
Chapter 1. Drugs and the Human Envirome
Chapter 2. Psychoactive Plants Used during Religious Rituals
Chapter 3. Substance Use Disorders and Comorbid Mental Illness: A Focus on
Epidemiological Data Regarding Mood and Anxiety Disorders
Chapter 4. Mephedrone and Mephedrone-Based Cocktails: Market, Analysis,
Mechanisms of Action, and Toxicity
Chapter 5. Substance-Induced Psychosis: Conceptual and Diagnostic
Challenges in Clinical Practice
Chapter 6. Sleep and Drug Addiction
Section B. Molecular and Cellular Aspects
Chapter 7. Hypothalamic and Midbrain Cells, Tyrosine Hydroxylase, and
Implications for Drug Addiction
Chapter 8. Oxytocin: Providing New Avenues for Treating and Understanding
Problematic Drug Use
Chapter 9. Role of D2-like Heteroreceptor Complexes in the Effects of
Cocaine, Morphine, and Hallucinogens
Chapter 10. Glutamate Receptors and Drug Addiction
Chapter 11. Effect of Interacting Nonsteroidal Anti-Inflammatory Agents
(NSAIDs) and Opioids on Mood: Pharmacodynamic Considerations in Misuse and
Abuse
Chapter 12. A Mini-Review on Different Commonly Used Abusive Drugs and the
Interactions of These Drugs and Chinese Herbs
Chapter 13. Interaction of Drugs of Addiction with DNA
Chapter 14. Drugs of Abuse and DNA Methylation in the Brain: Ethanol,
Cocaine, Amphetamine-Methamphetamine, Heroin, Antidepressants, and
Antipsychotics
Chapter 15. Orexin/Hypocretin System and Drug Addiction
Chapter 16. Reverse Translational Implications of Genome-Wide Association
Studies for Addiction Genetics
Chapter 17. Polymorphisms in the Delta Opioid Receptor Gene (OPRD1) and
Drug Addiction: Candidate Genes, Transgenic Mouse Models, and Genome-Wide
Association Studies
Chapter 18. Drug Addictions and Genetics of the Dopamine Pathway
Chapter 19. In Silico Chemogenomics Knowledgebase and Computational System
Neuropharmacology Approach for Cannabinoid Drug Research
Chapter 20. Cocaine- and Amphetamine-Regulated Transcript (CART) Peptide
and Drug Addiction
Section C. Structural and Functional Aspects
Chapter 21. The Cerebellar Landscape of Drug Addiction
Chapter 22. Movement Dysfunction as a Neuropathology of Illicit Stimulant
Abuse
Chapter 23. Left Hemispheric "Imbalance? in Drug Addiction
Chapter 24. Co-occurence of Substance Use and Personality Disorders:
Epidemiology, Etiopathogenesis, and Treatment
Chapter 25. Neonatal Abstinence Syndrome: Pharmacological Aspects
Chapter 26. Comorbidity between Substance Use Disorder and Severe Mental
Illness: Dual Diagnosis
Part II. Prescription Medications: Depressants
Section A. General Aspects
Chapter 27. Lormetazepam Addiction
Chapter 28. Prescribing and Dispensing of Benzodiazepines: Implications for
Dependence and Misuse
Section B. Molecular and Cellular Aspects
Chapter 29. Bidirectional Plasticity of Hippocampal Glutamate Receptors Is
Central to Expression of Benzodiazepine Withdrawal-Anxiety
Chapter 30. Effect of Chronic Benzodiazepine Exposure on GABAA Receptors:
Regulation of GABA/Benzodiazepine Site Interactions
Chapter 31. The K+-Cl¿ Cotransporter KCC2 and Zolpidem
Section C. Structural and Functional Aspects
Chapter 32. Benzodiazepine Misuse and Addiction. Risk Factors and Adverse
Behavioral Aspects
Chapter 33. Benzodiazepines, Age-Related Pharmacological Changes, and Risk
of Falls in Older Adults
Chapter 34. The Substantia Nigra Pars Reticulata in Sedative-Hypnotic
Withdrawal
Section D. Methods
Chapter 35. Assays for Benzodiazepines
Part III. Opioids and Morphine Derivatives
Section A. General Aspects
Chapter 36. Weak Opioid Analgesics Abuse and Addiction: A Comparison of the
Pharmacology and Pharmacoepidemiology of Codeine, Dihydrocodeine, and
Tramadol
Chapter 37. Maternal Codeine and Its Effect on the Fetus and Neonate: A
Focus on Pharmacogenomics, Neuropathology, and Withdrawal
Chapter 38. Methadone Usage, Misuse, and Addiction Processes: An Overview
Chapter 39. Tramadol, Usage, Misuse, and Addiction Processes
Chapter 40. Tramadol Abuse in the Elderly
Section B. Molecular and Cellular Aspects
Chapter 41. Oligodendrocyte Responses, Myelination, and Opioid Addiction
Treatments
Chapter 42. Opioids and TRPV1 Receptors
Chapter 43. Opioids and Serotonin Syndrome: An Example with Tramadol
Chapter 44. Opioid Dependence and the Adenylyl Cyclase/cAMP Signaling
Chapter 45. Central Nervous System Penetration of the Opioid Oxycodone
Chapter 46. Opioid Modulation of Voltage-Gated Calcium Currents
Chapter 47. The Neonatal Brain and Opioids
Chapter 48. Contribution of Spinal Cord mTORC1 to Chronic Opioid Tolerance
and Hyperalgesia
Chapter 49. Interaction of Codeine with DNA
Chapter 50. Fentanyl and Its Impact on Cell Functions
Chapter 51. Morphine and Trafficking of a Mu Opioid Receptor Interacting
Protein WLS
Chapter 52. Fas, Bcl-2, and Caspase-3 Protein and Morphine Addiction
Chapter 53. An Overview on Methadone-Intoxicated Patients
Chapter 54. Genetic Polymorphisms on OPRM1 Involved in Multiple Responses
of a Methadone Maintenance Population: Relationships with Insomnia, Libido,
Smoking, and Chemokines
Section C. Structural and Functional Aspects
Chapter 55. Modulation of Opioid Analgesic Reward by Inflammatory Agents
Chapter 56. Suicidal Behavior and Prescription Opioid Medication
Chapter 57. Codeine and Psychomotor Activity
Chapter 58. Neurobehavior of Neonates Born to Mothers Receiving Opioid
Maintenance Treatment: Methadone and Buprenorphine
Chapter 59. Prenatal Methadone and Behavioral Sensitization Induced by
Methamphetamine
Chapter 60. Treatments for Opioid Dependence and Methadone: Neurological
and Behavioral Aspects
Chapter 61. Cognitive Functioning in Methadone Use
Chapter 62. Sleep Disturbances in Methadone Maintenance Treatment (MMT)
Patients
Section D. Methods
Chapter 63. The Neuropathology of Drug Addictions and Substance Misuse:
Assays for Fentanyl
Chapter 64. Assays for Tramadol and Its Metabolites
Part IV. Stimulants and Other Compounds
Section A. General Aspects
Chapter 65. Methylphenidate Abuse: An Overview
Section B. Molecular and Cellular Aspects
Chapter 66. The Impact of Methylphenidate on Circadian Rhythms and Clock
Gene Expression
Section C. Structural and Functional Aspects
Chapter 67. The Characteristics of Acute and Chronic Methylphenidate, Dose,
and Route on Female and Male Animal Behavior
Chapter 68. Methylphenidate and Cognitive Performance
Chapter 69. Methylphenidate and Suicide
Chapter 70. The Effect of Methylphenidate on the Ventral Tegmental Area in
Adolescent and Adult Animals
Chapter 71. Dextromethorphan and Dextrorphan as Heuristic Rapid-Acting,
Conventional, and Treatment-Resistant Antidepressants, with Substance Abuse
Considerations
Part V. Caffeine and Areca (Betal Nut)
Section A. General Aspects
Chapter 72. Caffeine and Taurine and Energy Drink Abuse
Chapter 73. General Aspects of Areca Nut Addiction
Section B. Molecular and Cellular Aspects
Chapter 74. Caffeine, Adenosine A1 Receptors, and Brain Cortex. Molecular
Aspects
Chapter 75. Caffeine and the Developing Brain: Molecular and Cellular
Effects
Section C. Structural and Functional Aspects
Chapter 76. Effects of Caffeine and Its Cortical Response Studied by
Functional Brain Imaging
Chapter 77. Neurobehavioral Aspects of Caffeine
Chapter 78. Oral and Systemic Health Effects of Compulsive Areca Nut Use
Chapter 79. Areca Alkaloids and Schizophrenia
Chapter 80. Attentional Biases for Betel Nut Cues
Section D. Methods
Chapter 81. Quantitative Measurement of Caffeine by Optical Methods
Chapter 82. Betel Quid Dependence Scale
Part VI. Dual and Polydrug Abuse
Chapter 83. Types of Polydrug Usage
Chapter 84. Polypharmacy of Potentially Addictive Medications and the
Elderly
Chapter 85. New Insight into Alcohol and Nicotine Addiction:
Neurobiological Findings and Therapeutical Perspectives
Chapter 86. Multimodal Magnetic Resonance Neuroimaging and Cognition in
Polysubstance Users
Chapter 87. Neuropathological Studies in Polydrug Abusers
Part VII. Emerging Addictions and Drugs of Abuse
Chapter 88. Novel Drugs of Abuse: Cannabinoids, Stimulants, and
Hallucinogens
Chapter 89. Kratom (Mitragyna speciosa) Use, Addiction Potential, and Legal
Status
Chapter 90. Methylxanthines and Drug Dependence: Interactions and Toxicity
Chapter 91. The Neuropathology of Movement Disorders in
1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) and Methcathinone
(Ephedrone) Addictions
Chapter 92. 25C-NBOMe as a New Hallucinogen
Chapter 93. Pregabalin Abuse and Addiction
Part VIII. Non-Drug Addictions as Comparative Neuropathology
Chapter 94. Internet Gaming Disorder
Chapter 95. The Neuropathology of Internet Addiction
Chapter 96. Workaholism: An Addiction to Work
Chapter 97. Exercise Addiction
Chapter 98. Compulsive Buying-Features and Characteristics of Addiction
Chapter 99. Food Addiction: Applying Substance Use Disorder Criteria and
Characteristics to Identify Instances of Addictive-Like Eating
Chapter 100. Bulimia Nervosa as an Addiction
Chapter 101. Gambling Disorders: A Focus on Genetic Aspects
Mechanisms
Section A. General Aspects
Chapter 1. Drugs and the Human Envirome
Chapter 2. Psychoactive Plants Used during Religious Rituals
Chapter 3. Substance Use Disorders and Comorbid Mental Illness: A Focus on
Epidemiological Data Regarding Mood and Anxiety Disorders
Chapter 4. Mephedrone and Mephedrone-Based Cocktails: Market, Analysis,
Mechanisms of Action, and Toxicity
Chapter 5. Substance-Induced Psychosis: Conceptual and Diagnostic
Challenges in Clinical Practice
Chapter 6. Sleep and Drug Addiction
Section B. Molecular and Cellular Aspects
Chapter 7. Hypothalamic and Midbrain Cells, Tyrosine Hydroxylase, and
Implications for Drug Addiction
Chapter 8. Oxytocin: Providing New Avenues for Treating and Understanding
Problematic Drug Use
Chapter 9. Role of D2-like Heteroreceptor Complexes in the Effects of
Cocaine, Morphine, and Hallucinogens
Chapter 10. Glutamate Receptors and Drug Addiction
Chapter 11. Effect of Interacting Nonsteroidal Anti-Inflammatory Agents
(NSAIDs) and Opioids on Mood: Pharmacodynamic Considerations in Misuse and
Abuse
Chapter 12. A Mini-Review on Different Commonly Used Abusive Drugs and the
Interactions of These Drugs and Chinese Herbs
Chapter 13. Interaction of Drugs of Addiction with DNA
Chapter 14. Drugs of Abuse and DNA Methylation in the Brain: Ethanol,
Cocaine, Amphetamine-Methamphetamine, Heroin, Antidepressants, and
Antipsychotics
Chapter 15. Orexin/Hypocretin System and Drug Addiction
Chapter 16. Reverse Translational Implications of Genome-Wide Association
Studies for Addiction Genetics
Chapter 17. Polymorphisms in the Delta Opioid Receptor Gene (OPRD1) and
Drug Addiction: Candidate Genes, Transgenic Mouse Models, and Genome-Wide
Association Studies
Chapter 18. Drug Addictions and Genetics of the Dopamine Pathway
Chapter 19. In Silico Chemogenomics Knowledgebase and Computational System
Neuropharmacology Approach for Cannabinoid Drug Research
Chapter 20. Cocaine- and Amphetamine-Regulated Transcript (CART) Peptide
and Drug Addiction
Section C. Structural and Functional Aspects
Chapter 21. The Cerebellar Landscape of Drug Addiction
Chapter 22. Movement Dysfunction as a Neuropathology of Illicit Stimulant
Abuse
Chapter 23. Left Hemispheric "Imbalance? in Drug Addiction
Chapter 24. Co-occurence of Substance Use and Personality Disorders:
Epidemiology, Etiopathogenesis, and Treatment
Chapter 25. Neonatal Abstinence Syndrome: Pharmacological Aspects
Chapter 26. Comorbidity between Substance Use Disorder and Severe Mental
Illness: Dual Diagnosis
Part II. Prescription Medications: Depressants
Section A. General Aspects
Chapter 27. Lormetazepam Addiction
Chapter 28. Prescribing and Dispensing of Benzodiazepines: Implications for
Dependence and Misuse
Section B. Molecular and Cellular Aspects
Chapter 29. Bidirectional Plasticity of Hippocampal Glutamate Receptors Is
Central to Expression of Benzodiazepine Withdrawal-Anxiety
Chapter 30. Effect of Chronic Benzodiazepine Exposure on GABAA Receptors:
Regulation of GABA/Benzodiazepine Site Interactions
Chapter 31. The K+-Cl¿ Cotransporter KCC2 and Zolpidem
Section C. Structural and Functional Aspects
Chapter 32. Benzodiazepine Misuse and Addiction. Risk Factors and Adverse
Behavioral Aspects
Chapter 33. Benzodiazepines, Age-Related Pharmacological Changes, and Risk
of Falls in Older Adults
Chapter 34. The Substantia Nigra Pars Reticulata in Sedative-Hypnotic
Withdrawal
Section D. Methods
Chapter 35. Assays for Benzodiazepines
Part III. Opioids and Morphine Derivatives
Section A. General Aspects
Chapter 36. Weak Opioid Analgesics Abuse and Addiction: A Comparison of the
Pharmacology and Pharmacoepidemiology of Codeine, Dihydrocodeine, and
Tramadol
Chapter 37. Maternal Codeine and Its Effect on the Fetus and Neonate: A
Focus on Pharmacogenomics, Neuropathology, and Withdrawal
Chapter 38. Methadone Usage, Misuse, and Addiction Processes: An Overview
Chapter 39. Tramadol, Usage, Misuse, and Addiction Processes
Chapter 40. Tramadol Abuse in the Elderly
Section B. Molecular and Cellular Aspects
Chapter 41. Oligodendrocyte Responses, Myelination, and Opioid Addiction
Treatments
Chapter 42. Opioids and TRPV1 Receptors
Chapter 43. Opioids and Serotonin Syndrome: An Example with Tramadol
Chapter 44. Opioid Dependence and the Adenylyl Cyclase/cAMP Signaling
Chapter 45. Central Nervous System Penetration of the Opioid Oxycodone
Chapter 46. Opioid Modulation of Voltage-Gated Calcium Currents
Chapter 47. The Neonatal Brain and Opioids
Chapter 48. Contribution of Spinal Cord mTORC1 to Chronic Opioid Tolerance
and Hyperalgesia
Chapter 49. Interaction of Codeine with DNA
Chapter 50. Fentanyl and Its Impact on Cell Functions
Chapter 51. Morphine and Trafficking of a Mu Opioid Receptor Interacting
Protein WLS
Chapter 52. Fas, Bcl-2, and Caspase-3 Protein and Morphine Addiction
Chapter 53. An Overview on Methadone-Intoxicated Patients
Chapter 54. Genetic Polymorphisms on OPRM1 Involved in Multiple Responses
of a Methadone Maintenance Population: Relationships with Insomnia, Libido,
Smoking, and Chemokines
Section C. Structural and Functional Aspects
Chapter 55. Modulation of Opioid Analgesic Reward by Inflammatory Agents
Chapter 56. Suicidal Behavior and Prescription Opioid Medication
Chapter 57. Codeine and Psychomotor Activity
Chapter 58. Neurobehavior of Neonates Born to Mothers Receiving Opioid
Maintenance Treatment: Methadone and Buprenorphine
Chapter 59. Prenatal Methadone and Behavioral Sensitization Induced by
Methamphetamine
Chapter 60. Treatments for Opioid Dependence and Methadone: Neurological
and Behavioral Aspects
Chapter 61. Cognitive Functioning in Methadone Use
Chapter 62. Sleep Disturbances in Methadone Maintenance Treatment (MMT)
Patients
Section D. Methods
Chapter 63. The Neuropathology of Drug Addictions and Substance Misuse:
Assays for Fentanyl
Chapter 64. Assays for Tramadol and Its Metabolites
Part IV. Stimulants and Other Compounds
Section A. General Aspects
Chapter 65. Methylphenidate Abuse: An Overview
Section B. Molecular and Cellular Aspects
Chapter 66. The Impact of Methylphenidate on Circadian Rhythms and Clock
Gene Expression
Section C. Structural and Functional Aspects
Chapter 67. The Characteristics of Acute and Chronic Methylphenidate, Dose,
and Route on Female and Male Animal Behavior
Chapter 68. Methylphenidate and Cognitive Performance
Chapter 69. Methylphenidate and Suicide
Chapter 70. The Effect of Methylphenidate on the Ventral Tegmental Area in
Adolescent and Adult Animals
Chapter 71. Dextromethorphan and Dextrorphan as Heuristic Rapid-Acting,
Conventional, and Treatment-Resistant Antidepressants, with Substance Abuse
Considerations
Part V. Caffeine and Areca (Betal Nut)
Section A. General Aspects
Chapter 72. Caffeine and Taurine and Energy Drink Abuse
Chapter 73. General Aspects of Areca Nut Addiction
Section B. Molecular and Cellular Aspects
Chapter 74. Caffeine, Adenosine A1 Receptors, and Brain Cortex. Molecular
Aspects
Chapter 75. Caffeine and the Developing Brain: Molecular and Cellular
Effects
Section C. Structural and Functional Aspects
Chapter 76. Effects of Caffeine and Its Cortical Response Studied by
Functional Brain Imaging
Chapter 77. Neurobehavioral Aspects of Caffeine
Chapter 78. Oral and Systemic Health Effects of Compulsive Areca Nut Use
Chapter 79. Areca Alkaloids and Schizophrenia
Chapter 80. Attentional Biases for Betel Nut Cues
Section D. Methods
Chapter 81. Quantitative Measurement of Caffeine by Optical Methods
Chapter 82. Betel Quid Dependence Scale
Part VI. Dual and Polydrug Abuse
Chapter 83. Types of Polydrug Usage
Chapter 84. Polypharmacy of Potentially Addictive Medications and the
Elderly
Chapter 85. New Insight into Alcohol and Nicotine Addiction:
Neurobiological Findings and Therapeutical Perspectives
Chapter 86. Multimodal Magnetic Resonance Neuroimaging and Cognition in
Polysubstance Users
Chapter 87. Neuropathological Studies in Polydrug Abusers
Part VII. Emerging Addictions and Drugs of Abuse
Chapter 88. Novel Drugs of Abuse: Cannabinoids, Stimulants, and
Hallucinogens
Chapter 89. Kratom (Mitragyna speciosa) Use, Addiction Potential, and Legal
Status
Chapter 90. Methylxanthines and Drug Dependence: Interactions and Toxicity
Chapter 91. The Neuropathology of Movement Disorders in
1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) and Methcathinone
(Ephedrone) Addictions
Chapter 92. 25C-NBOMe as a New Hallucinogen
Chapter 93. Pregabalin Abuse and Addiction
Part VIII. Non-Drug Addictions as Comparative Neuropathology
Chapter 94. Internet Gaming Disorder
Chapter 95. The Neuropathology of Internet Addiction
Chapter 96. Workaholism: An Addiction to Work
Chapter 97. Exercise Addiction
Chapter 98. Compulsive Buying-Features and Characteristics of Addiction
Chapter 99. Food Addiction: Applying Substance Use Disorder Criteria and
Characteristics to Identify Instances of Addictive-Like Eating
Chapter 100. Bulimia Nervosa as an Addiction
Chapter 101. Gambling Disorders: A Focus on Genetic Aspects